Amylyx Pharmaceuticals
AMLX | NASDAQ
$27.80
-$2.49 (-8.22%)
At close: Nov 16, 2026, 4:00 PM ET
$27.67
-$0.13 (-0.47%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Amylyx Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Joshua Cohen | Co-Founder, Co-CEO & Director |
| Justin Klee | Co-CEO & Director |
| Gina Mazzariello | Chief Legal Officer & General Counsel |
| James Frates | Chief Financial Officer |
| Camille L. Bedrosian | Chief Medical Officer |
| Linda A. Arsenault | Chief Human Resources Officer |
| Lindsey Allen | Head of Investor Relations & Communications |
| Machelle Manuel | Vice President & Head of Global Medical Affairs |
| Tammy Sarnelli | Global Head of Regulatory Affairs |
| Tom Holmes | Chief Technical Operations Officer |
Amylyx Pharmaceuticals
| Country | United States |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Joshua Cohen |
Contact Details
55 Cambridge Parkway Cambridge,
Massachusetts 02142 United States
Stock Details
| Ticker Symbol | AMLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001658551 |
| CUSIP Number | 03237H101 |
| ISIN Number | US03237H1014 |
| SIC Code | 2834 |
Recent News
- 1 day ago / seekingalpha.comAmylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript
- 2 days ago / businesswire.comAmylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
- 11 days ago / seekingalpha.comAmylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript
- 12 days ago / marketbeat.comAmylyx Pharmaceuticals Q3 Earnings Call Highlights
- 14 days ago / businesswire.comAmylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
- 15 days ago / businesswire.comAmylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
- 1 month ago / schaeffersresearch.com11 Stocks Most Likely to See a Short Squeeze Rally
- 1 month ago / businesswire.comAmylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
- 2 months ago / schaeffersresearch.com10 Stocks With Massive Short Squeeze Potential
- 2 months ago / seekingalpha.comAmylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Add to Watchlist
Select watchlists to add or remove AMLX